DEF: LanzaTech Seeks Shareholder Approval for Massive Dilution and Reverse Stock Split Amidst Nasdaq Delisting Threat and Urgent Capital Needs

Sentiment:

Proxy Statement


LanzaTech Global, Inc. is calling for a 2025 Annual Meeting of Stockholders to approve critical proposals including a significant increase in authorized shares, a 100-for-1 reverse stock split, and a potential capital raise, all aimed at addressing Nasdaq listing compliance and securing essential funding, which will result in substantial shareholder dilution.

Capital raiseOn May 7, 2025, LanzaTech issued and sold 20,000,000 shares of Series A Convertible Senior Preferred Stock to LanzaTech Global SPV, LLC (controlled by Khosla Ventures) for an aggregate purchase price of $40 million.The company agreed to issue a warrant to the Purchaser to buy 780,000,000 shares of Common Stock at an exercise price of $0.0000001 per share, contingent on stockholder approvals and a subsequent financing.LanzaTech is obligated to use reasonable best efforts to consummate a 'Subsequent Financing' by selling Common Stock to accredited investors at $0.05 per share (subject to adjustment), aiming to raise between $35 million and $60 million.The 'Subsequent Financing' must be consummated no later than 45 days following receipt of the Requisite Stockholder Approvals.The company may also pursue an 'Other Financing' with the consent of the Majority Holders of Preferred Stock, in lieu of the 'Subsequent Financing'.
Worse than expectedThe company's stock price has fallen below Nasdaq's $1.00 minimum bid price requirement, indicating poor market performance and triggering a delisting threat.The necessity for a 100-for-1 reverse stock split highlights a significant decline in share value.The proposed capital raise, including the issuance of a warrant and a subsequent financing, will result in an estimated 853.6% dilution of existing common stock, indicating a distressed need for capital at a very low valuation ($0.05 per share pre-split).The company explicitly states it cannot assure sufficient liquidity to make a mandatory redemption payment for the Preferred Stock if stockholder approvals are not obtained, signaling severe financial strain.The company has consistently reported significant net losses, with 2024's net loss at $(137.70) million, showing a lack of profitability and increasing losses over the past three years.

Summary

  • LanzaTech Global, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Monday, July 28, 2025, at 2:00 p.m. Central Time.
  • Key proposals include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
  • The company is seeking stockholder approval to increase authorized Common Stock from 600,000,000 to 2,580,000,000 shares to facilitate the issuance of shares related to a warrant and a future financing.
  • A 100-for-1 reverse stock split is proposed to increase the per-share trading price of Common Stock to meet Nasdaq's $1.00 minimum bid price requirement, following a non-compliance notice received on March 13, 2025.
  • Stockholders will vote on amendments to the Certificate of Incorporation to permit action by written consent and to decrease the par value of Common Stock from $0.0001 to $0.0000001 per share.
  • Approval is sought for potential 'change of control' and issuance of shares exceeding 19.9% of outstanding Common Stock under Nasdaq Listing Rules 5635(b) and 5635(d), respectively, due to the scale of the proposed transactions.
  • The company recently consummated a Preferred Stock Issuance on May 7, 2025, selling 20,000,000 shares of Series A Preferred Stock to LanzaTech Global SPV, LLC (controlled by Khosla Ventures) for $40 million.
  • A warrant to purchase 780,000,000 shares of Common Stock at an exercise price of $0.0000001 per share is to be issued to the Purchaser, contingent on stockholder approvals and a subsequent financing.
  • LanzaTech is obligated to seek a 'Subsequent Financing' of $35 million to $60 million by selling Common Stock at $0.05 per share (pre-split), which could result in the issuance of 700,000,000 to 1,200,000,000 shares.
  • Failure to obtain stockholder approvals for the increased authorized shares and subsequent financing would trigger a Mandatory Redemption event for the Preferred Stock, for which the company cannot assure sufficient liquidity.
  • The company reported a Net Loss of $(137.70) million for fiscal year 2024, compared to $(134.10) million in 2023 and $(76.36) million in 2022.
  • Audit fees for 2024 were $2,203,592, and total fees for 2023 were $2,478,471.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the severe dilution required, the Nasdaq delisting threat, and the explicit statement of potential liquidity issues if the capital raise and associated proposals are not approved. While the company is taking steps to address its challenges, the underlying financial distress and the magnitude of dilution indicate a very difficult situation for existing shareholders.

Positives

  • The proposed amendments to the Certificate of Incorporation, including allowing stockholder action by written consent, enhance corporate governance and stockholder rights.
  • The company is actively seeking additional capital, which is critical for its long-term success and operations.
  • The Board of Directors is committed to maintaining the company's Nasdaq listing, which is beneficial for stock liquidity and investor appeal.
  • New directors Reyad Fezzani, Thierry Pilenko, and Jill Frizzley bring extensive experience in renewable energy, technology, and corporate governance to the Board.

Negatives

  • The proposed transactions, including the warrant exercise and subsequent financing, could result in significant dilution of existing stockholders' ownership and voting interests, potentially increasing outstanding shares by 853.6% pre-split.
  • The company received a Nasdaq notice on March 13, 2025, for failing to meet the $1.00 minimum bid price requirement, indicating a struggling stock performance.
  • Failure to obtain stockholder approvals for the increased authorized shares and subsequent financing would trigger a Mandatory Redemption event for the Preferred Stock, and the company cannot assure sufficient liquidity to make this payment.
  • The issuance of shares will concentrate ownership, with Khosla Ventures and its affiliates potentially owning approximately 48.7% of outstanding Common Stock post-transaction, which could limit trading activity and influence corporate decisions.
  • The company has experienced significant net losses: $(137.70) million in 2024, $(134.10) million in 2023, and $(76.36) million in 2022.
  • There is no assurance that the reverse stock split will increase the stock price proportionately or attract new investors, and it may decrease liquidity and increase transaction costs for odd lots.

Risks

  • Substantial dilution of existing stockholders' economic and voting interests due to the issuance of new shares upon conversion of Preferred Stock, exercise of the Warrant, and a future Financing.
  • Risk of delisting from Nasdaq if the company fails to regain compliance with the $1.00 minimum bid price rule, or if Nasdaq exercises its discretionary authority due to substantial dilution.
  • Inability to raise necessary capital if the Requisite Stockholder Approvals are not obtained, which would greatly limit the company's operations.
  • Mandatory Redemption event for Preferred Stock if sufficient authorized shares are not obtained for the Warrant exercise and Subsequent Financing, with no assurance of sufficient liquidity to make the payment.
  • Concentration of share ownership in a limited number of holders (e.g., Khosla Ventures and affiliates potentially owning ~48.7% post-transaction), which could further limit trading activity and allow significant influence over company matters.
  • Uncertainty regarding the effectiveness of the reverse stock split in increasing and sustaining the stock price, potentially leading to decreased liquidity and higher transaction costs.
  • The company has not entered into definitive agreements for a Financing, and there is no assurance when or if such agreements will be reached.

Future Outlook

The company is actively seeking additional capital through a 'Subsequent Financing' or 'Other Financing' to support its operations, contingent on obtaining Requisite Stockholder Approvals. The 'Subsequent Financing' is targeted to raise between $35 million and $60 million at a price of $0.05 per share (pre-split) and must be consummated within 45 days of receiving stockholder approvals. The company expects to file the Certificate of Amendment for the Increased Authorized Share Proposal, Par Value Amendment, and Written Consent Amendment promptly after the Annual Meeting, and the Reverse Stock Split Amendment after the Increased Authorized Share Amendment. The Board will determine the exact timing of the Reverse Stock Split based on market conditions and the need to maintain Nasdaq listing.

Management Comments

  • "The Annual Meeting is intended to satisfy our obligations under the Purchase Agreement and to provide us with greater flexibility to seek additional financing."
  • "Our Board of Directors strongly recommends you vote FOR each of the following proposals."
  • "We believe that hosting a virtual Annual Meeting is in the best interest of the Company and its stockholders. We believe a virtual Annual Meeting enables increased stockholder attendance and participation because stockholders can participate from any location around the world while reducing the carbon footprint that would be required for stockholders to travel to and attend an in-person meeting."
  • "We are actively seeking additional capital and we have entered into confidentiality agreements with various potential investors, including certain of our existing stockholders."
  • "We and our Board believe that it is advisable and in our and our stockholders best interests, and critical to our long-term success, to increase the number of authorized shares of our Common Stock."
  • "The Board has determined that it is advisable and in the best interests of the Company and its stockholders to reduce the number of shares of Common Stock outstanding with the primary intent of increasing the per share trading price of the Common Stock in order to meet the listing requirements of the Nasdaq Capital Market."
  • "Our Board is committed to strong corporate governance and believes in maintaining policies and practices that serve the best interests of all stockholders."

Industry Context

LanzaTech operates in the capital-intensive renewable energy and biotechnology sector, which often requires significant funding for research, development, and commercialization of new technologies. The need for a substantial capital raise and the challenges in maintaining Nasdaq listing due to a low share price are common issues for companies in this space, especially those in growth stages or facing market headwinds. The proposed financing structure, involving preferred stock, warrants, and a subsequent equity raise, reflects a common strategy for companies seeking to secure funding from strategic investors or existing large shareholders when traditional public market financing might be challenging due to valuation or market conditions. The emphasis on reducing carbon footprint for the annual meeting aligns with broader ESG trends in the industry.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Class II DirectorGary Rieschel2025-07-28Will not seek re-election and will step down at the conclusion of the Annual Meeting.
Class II DirectorReyad Fezzani2025-01-01Appointment to the Board.
Class I DirectorThierry Pilenko2025-01-01Appointment to the Board.
Class III DirectorJill Frizzley2025-03-01Appointment to the Board.
Chief Financial OfficerSushmita Koyanagi2025-06-02Promotion from Chief Accounting Officer.
Chief Accounting OfficerSushmita KoyanagiMichael Heraty2025-06-02Promotion from Vice President Internal Audit & SOX Compliance.
General Counsel and Corporate SecretaryJoseph Blasko2025-06-13Resignation from position.
Interim General CounselAmanda Koenig Fuisz2025-06-13Promotion from Deputy General Counsel.
Deputy General Counsel and Corporate SecretaryRyan Replogle2025-06-13Promotion from Deputy General Counsel.
PresidentAura Cuellar2024-03-01Promotion from Executive Vice President of Growth and Strategic Projects.
Chief Technology OfficerRobert Conrado, Ph.D.2024-03-01Promotion from Vice President of Engineering Design and Development.
Chief Innovation OfficerMichael Kpke, Ph.D.2023-07-01Promotion from Vice President Synthetic Biology.
Chief Science OfficerZarath Summers, Ph.D.2023-07-01Appointment to position.
Chief People OfficerChad Thompson2022-10-01Appointment to position.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Bylaw Amendment ProposalProposal to amend the Certificate of Incorporation to permit stockholders to act by written consent, enhancing stockholder rights.Upon filing of Certificate of Amendment (if approved)Increases stockholder influence by allowing actions without a physical meeting, potentially streamlining certain corporate decisions.
Board CompositionThe Board consists of nine directors, generally divided into three classes with three-year terms. Holders of Preferred Stock are entitled to elect one Series A Director, who is not included in any class.OngoingMaintains a staggered board structure, which can provide stability but may also make hostile takeovers more difficult. The Series A Director provision grants specific governance rights to Preferred Stockholders.
Director IndependenceA majority of Board members (Barbara Byrne, Reyad Fezzani, Jill Frizzley, Nigel Gormly, Dorri McWhorter, Jim Messina, Thierry Pilenko, Gary Rieschel) are determined to be independent under Nasdaq listing standards.OngoingEnsures strong independent oversight of management and adherence to best practices for public companies.
Board Leadership StructureThe CEO (Dr. Jennifer Holmgren) also serves as Chair of the Board, with Jim Messina serving as Lead Independent Director.OngoingCombines leadership roles, which can provide unified vision, but is counterbalanced by a strong Lead Independent Director to ensure independent oversight and stockholder representation.
Risk Oversight DelegationThe Board oversees risk management directly and through its standing committees, with primary responsibility for cybersecurity matters delegated to the Audit Committee.OngoingEstablishes a structured approach to risk management, integrating it into committee responsibilities and ensuring regular reporting to the full Board.
Executive Compensation Recovery PolicyAdopted an executive compensation recovery (clawback) policy compliant with Nasdaq and SEC rules, allowing mandatory recoupment of erroneously-awarded incentive-based compensation.2023-08-31Enhances accountability for executive officers and aligns compensation with accurate financial reporting, protecting shareholder interests.
Insider Trading and Hedging PoliciesMaintains an insider trading policy and a policy prohibiting employees and directors from hedging, short-selling, purchasing on margin, or pledging company securities.OngoingPromotes ethical conduct and prevents conflicts of interest, aligning the interests of insiders with long-term shareholder value.

Related Party Transactions

  • On May 7, 2025, LanzaTech entered into a Series A Convertible Senior Preferred Stock Purchase Agreement with LanzaTech Global SPV, LLC, an entity controlled by Khosla Ventures (a beneficial owner of more than 5% of the company's voting securities).
  • Pursuant to this agreement, LanzaTech issued and sold 20,000,000 shares of Preferred Stock to the Purchaser for $40 million.
  • The company also agreed to issue a warrant to the Purchaser to purchase 780,000,000 shares of Common Stock at a nominal exercise price, contingent on stockholder approvals and a subsequent financing.
  • Khosla Ventures, as the Majority Holder of Preferred Stock, has consent rights over any 'Other Financing' and certain other corporate actions, and has agreed to vote its pre-May 7, 2025 Common Stock in favor of the Requisite Stockholder Approvals.

Stakeholder Impact

  • **Shareholders**: Will experience significant dilution (estimated 853.6% pre-split) if the capital raise and associated proposals are approved. Their voting power will also be diluted, and ownership will be concentrated in a few large holders. The reverse stock split aims to maintain Nasdaq listing, which could benefit liquidity, but its effectiveness is uncertain. Failure to approve proposals could lead to delisting and a mandatory redemption event for Preferred Stock, potentially impacting the company's ability to make payments.
  • **Employees**: The company's ability to raise capital is critical for its continued operations and long-term success, which directly impacts job security and future opportunities. Equity awards held by employees will be proportionately adjusted by the reverse stock split.
  • **Creditors**: The company's ability to secure additional financing and avoid a mandatory redemption event for Preferred Stock (which could trigger liquidity issues) is crucial for its financial stability and ability to meet its obligations.
  • **Customers/Suppliers**: The successful capital raise and continued operations are essential for the company to deliver on its projects and maintain its supply chain, ensuring business continuity.

Next Steps

  • Hold the 2025 Annual Meeting of Stockholders on July 28, 2025, to vote on the proposed resolutions.
  • If approved, file the Certificate of Amendment for the Increased Authorized Share Proposal, Par Value Amendment, and Written Consent Amendment promptly following the Annual Meeting.
  • If approved, file the Reverse Stock Split Amendment promptly following the conclusion of the Annual Meeting and after filing of the Increased Authorized Share Amendment.
  • Continue to seek additional capital through a 'Subsequent Financing' or 'Other Financing' following stockholder approvals.
  • Work to regain compliance with Nasdaq's $1.00 minimum bid price rule by September 9, 2025, potentially through the reverse stock split.
  • The Board and Audit Committee will continue to oversee IT systems and cybersecurity, with quarterly updates from the CISO.

Key Dates

DateDescription
2022-01-01Start of fiscal year 2022 for financial reporting.
2022-12-31End of fiscal year 2022 for financial reporting.
2023-01-01Start of fiscal year 2023 for financial reporting.
2023-02-08Date of vesting for certain restricted stock units.
2023-02-21Date Schedule 13G filed by Guardians of New Zealand Superannuation.
2023-03-06Date of first installment time vesting for stock options and restricted stock units granted on May 2, 2023.
2023-05-02Grant date for certain stock options, performance share units, and restricted stock units.
2023-07-01Effective date for Michael Kpke's promotion to Chief Innovation Officer and Zarath Summers' promotion to Chief Science Officer.
2023-08-31Date of adoption of executive compensation recovery policy.
2023-10-01Effective date for Chad Thompson's promotion to Chief People Officer.
2023-12-31End of fiscal year 2023 for financial reporting.
2024-01-01Start of fiscal year 2024 for financial reporting.
2024-01-08Date of second installment of Joseph Blasko's signing bonus payment.
2024-01-01Date of full vesting for stock options granted on June 26, 2020.
2024-01-01Effective date for Reyad Fezzani and Thierry Pilenko's appointment as directors.
2024-02-08Vesting date for certain restricted stock units for directors.
2024-03-04Date of stock option exercise transaction by Freya Burton.
2024-03-05Date of stock option exercise transaction by Freya Burton.
2024-03-06Vesting date for certain restricted stock units for executive officers.
2024-03-13Date LanzaTech received written notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule.
2024-03-01Effective date for Aura Cuellar's promotion to President and Robert Conrado's promotion to Chief Technology Officer.
2024-03-01Effective date for Jill Frizzley's appointment to the Board.
2024-04-04Date of RSU award for non-employee directors.
2024-04-05Grant date for certain restricted stock units and stock options.
2024-04-25Date Nimesh Patel resigned.
2024-05-13Date of last installment of Aura Cuellar's signing bonus payment.
2024-08-01Effective date for Nigel Gormly's new role at Centre for Sustainable Finance: Toit Tahua.
2024-12-01Effective date for Sushmita Koyanagi's role as Chief Accounting Officer.
2024-12-31End of fiscal year 2024 for financial reporting.
2025-05-07Date of entry into Series A Convertible Senior Preferred Stock Purchase Agreement and consummation of Preferred Stock Issuance.
2025-05-09Date of Schedule 13D/A filing by Khosla Ventures.
2025-06-02Date of Amendment No. 1 to the Series A Convertible Senior Preferred Stock Purchase Agreement, extending warrant issuance and financing consummation dates. Also, effective date for Sushmita Koyanagi's promotion to CFO and Michael Heraty's promotion to Chief Accounting Officer.
2025-06-03Record Date for the 2025 Annual Meeting of Stockholders.
2025-06-06Closing price of Common Stock on Nasdaq Capital Market was $0.29.
2025-06-13Effective date for Amanda Koenig Fuisz's promotion to Interim General Counsel and Ryan Replogle's promotion to Deputy General Counsel and Corporate Secretary. Also, Joseph Blasko's resignation date.
2025-06-18Approximate date of mailing Notice of Internet Availability of Proxy Materials.
2025-07-25Deadline for beneficial owners to email legal proxy to CST for voting at the Annual Meeting (2:00 p.m. Central Time).
2025-07-27Deadline for Internet proxy votes (11:59 p.m. Eastern Daylight Time).
2025-07-28Date of the 2025 Annual Meeting of Stockholders.
2025-09-09First Compliance Date for regaining Nasdaq's $1.00 minimum bid price requirement.
2026-02-18Deadline for stockholder proposals to be included in the 2026 Annual Meeting proxy statement under Rule 14a-8 (unless meeting date changes).
2026-03-30Earliest date for stockholders to provide notice for proposals/nominations for 2026 Annual Meeting under Bylaws (if meeting date is July 28, 2026).
2026-04-29Latest date for stockholders to provide notice for proposals/nominations for 2026 Annual Meeting under Bylaws (if meeting date is July 28, 2026).
2026-05-07Termination date for the Warrant if Issuance Time does not occur prior to this date.
2028-02-10Deadline for performance share units granted on May 2, 2023, to meet vesting conditions.
2028-07-28Term expiration for Class II directors elected at the 2025 Annual Meeting.
2030-06-26Expiration date for stock options granted on June 26, 2020.
2033-05-02Expiration date for stock options granted on May 2, 2023.
2034-04-05Expiration date for stock options granted on April 5, 2024.

Recommendation

strong sell

Keywords

LanzaTech, SEC Filing, Proxy Statement, DEF 14A, Annual Meeting, Stockholder Proposals, Capital Raise, Preferred Stock, Warrant, Subsequent Financing, Reverse Stock Split, Share Dilution, Nasdaq Listing, Delisting Risk, Corporate Governance, Executive Compensation, Biotechnology, Renewable Energy, Carbon Capture, Sustainable Fuels

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.